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Mineralization of soft tissues is an abnormal process
that occurs in any body tissue and can greatly in-
crease morbidity and mortality. Vitamin K-depen-
dent (VKD) proteins play a crucial role in these
processes; matrix Gla protein is considered one of
the most relevant physiological inhibitors of soft
tissue calcification know to date. Several studies
have suggested that other , still unknown, VKD pro-
teins might also be involved in soft tissue calcifica-
tion pathologies. We have recently identified in
sturgeon a new VKD protein, Gla-rich protein
(GRP) , which contains the highest ratio between
number of Gla residues and size of the mature pro-
tein so far identified. Although mainly expressed in
cartilaginous tissues of sturgeon, in rat GRP is
present in both cartilage and bone. We now show
that GRP is a circulating protein that is also ex-
pressed and accumulated in soft tissues of rats and
humans, including the skin and vascular system in
which, when affected by pathological calcifica-
tions , GRP accumulates at high levels at sites of
mineral deposition, indicating an association with
calcification processes. The high number of Gla res-
idues and consequentmineral binding affinity properties
strongly suggest that GRP may directly influence min-
eral formation, thereby playing a role in processes in-
volving connective tissue mineralization. (Am J Pathol
2009, 175:2288–2298; DOI: 10.2353/ajpath.2009.090474)
Extracellular matrix (ECM) calcification can be either a
physiological or a pathological process depending on
site and time of occurrence. Physiological ECM calcifica-
tion is restricted to bone and to the hypertrophic zones of
growth plate cartilage, whereas pathological or ectopic
ECM calcification, defined as inappropriate biomineral-
ization occurring in soft tissues and consisting of calcium
phosphate salts that include hydroxyapatite, is an abnor-
mal process that can occur virtually in any tissue of the
body.1 However, skin, kidney, tendons, and the cardio-
vascular system appear particularly prone to develop this
pathology.2
First considered to be a passive process occurring as
a nonspecific response to tissue injury or necrosis, recent
evidence now indicates that ECM calcification is a natu-
rally occurring process that must be actively inhibited
and starts to appear as soon as inhibitors are removed
from the matrix.1,3,4 In a healthy organism, cells appear to
synthesize natural inhibitors of mineralization that prevent
ectopic calcification, which initiates when disequilibrium
occurs between expression of calcification inhibitors and
enhancers, emphasizing the need for a tight regulation to
prevent ectopic calcifications.
Key genes known to be involved in the regulation of
this complex process are those acting as calcification
inhibitors such as matrix Gla protein (MGP), osteocalcin
(BGP), bone sialoprotein (BSP), osteoprotegerin (Opg),
and fetuin.1,3 Among those, MGP, a vitamin K-dependent
Supported in part by Centre of Marine Sciences (M.L.C. and D.C.S.),
project POCTI MAR 57921 2004 (D.C.S., M.L.C., C.S.B.V.) and NIH grant
HL58090 (to P.A.P.). C.S.B.V. was the recipient of Ph.D. fellowship SFRH/
BD/9077/2002 from the Portuguese Science and Technology Foundation.
Methods and tools described and obtained during the course of this work
are included in United States priority application 61/136.315, August 27,
2008, and PCT patent application PCT/PT2009000046, August 27, 2009.
Accepted for publication August 21, 2009.
D.C.S., M.L.C., and C.S.B.V. are cofounders of GenoGla Diagnostics.
Supplemental material for this article can be found on http://ajp.
amjpathol.org.
Address reprint requests to Dina C. Simes, Ph.D., Centre of Marine
Sciences (CCMAR), University of Algarve, Campus de Gambelas, 8005-
139 Faro, Portugal, E-mail: dsimes@ualg.pt.
The American Journal of Pathology, Vol. 175, No. 6, December 2009
Copyright © American Society for Investigative Pathology
DOI: 10.2353/ajpath.2009.090474
2288
protein (VKD), is widely accepted as playing a pivotal
role in preventing soft tissue calcification, local mineral-
ization of the vascular wall,5 and more recently, skin
elastic fiber mineralization in pseudoxanthoma elasticum
(PXE)6–8 and in scleroderma with and without calcino-
sis.9 It is also known that several factors, such as insuf-
ficient intake of vitamin K, mutations in the -carboxylase
enzyme, and warfarin treatment, which can all induce
arterial10–12 and skin calcifications,7,13–15 may act by
reducing or abolishing -carboxylation of VKD proteins.
Those pathologies have also been associated with a loss
of MGP function, until now considered to be the central
Gla protein for prevention of connective tissue mineral-
ization, both in the vascular system and skin. Although
many efforts have been made to understand the mech-
anisms controlling these abnormal calcifications, the ex-
istence of other potential, still unknown, calcification in-
hibitors has been suggested to explain some reported
phenotypes and occurrences that are not completely
justified by the presence or absence of MGP.1,16,17
We have recently identified in sturgeon a new VKD
protein, Gla-rich protein (GRP), with an unprecedented
high content of Gla residues and uncommonly high ca-
pacity to bind calcium, with orthologs in all taxonomic
groups of vertebrates and highly conserved throughout
evolution (78% identity between sturgeon and human
GRP).18 GRP mRNA was found to be highly expressed in
sturgeon cartilaginous tissues, and in rat skeletal tissues,
both cartilage and bone, which invalidated the concept
that this protein could be solely a specific marker for
distal chondrocytes, as previously proposed by others.18
In this study we show, for the first time, that GRP is a
circulating protein also expressed and accumulated in
soft tissues like skin and vascular system of rats and
humans and that it is clearly associated with calcification
pathologies in these tissues, being highly accumulated at
sites of ectopic mineral deposits. Furthermore, the exten-
sive number of Gla residues (16 Gla residues in sturgeon
and, by comparison, 15 in all mammals) and the absence
of other identifiable functional domains, together with our
in vivo and in vitro evidence for a high mineral binding
affinity, strongly suggest that GRP might be a potent
physiological modulator of soft tissue calcification, acting
by directly influence mineral formation and or recruit-
ment, and an important new player in the complexity of
phenotypes involving connective tissue mineralization,




This study was approved by the Faro Hospital and Lisbon
Central Hospital ethics committee. We included in our
study patients with stage 5 chronic kidney disease who
underwent surgery for arteriovenous fistula creation. A
sample of the radial artery wall was collected at the time
of surgery from each patient. Calcified and noncalcified
carotid samples were also collected at autopsy. Skin
biopsies were taken under local anesthesia from the af-
fected skin of PXE, dermatomyositis with calcinosis, and
scleroderma with calcinosis (lateral neck or axilla) pa-
tients. All patients exhibited clinical signs and were diag-
nosed for the corresponding pathology. Control skin bi-
opsies were obtained from forearm regions of volunteer
healthy subjects. Human blood was collected from vol-
unteer healthy subjects by venipuncture at Faro Hospital.
Informed consent was obtained from all participants.
Pig ears were obtained from the local slaughterhouse,
immediately frozen for transport, and kept at 80° until
further processing. Rat skin and blood samples were
obtained from Mus musculus specimens maintained at
the University of Algarve animal facilities.
Gene Expression by Quantitative Real-Time
Polymerase Chain Reaction
Total RNA was extracted from rat adult tissues (including
bony, cartilaginous, and major soft tissues) as de-
scribed.19 One microgram of total RNA was treated with
RQ1 RNase-free DNase (Promega, Madison, WI) and
reverse-transcribed at 37°C with MMLV-RT (Invitrogen,
San Diego, CA) using specific reverse primers RnGRP1R
(5-CACTCAAAAACAAGACAAAGCAAACATCCG-3),
RnGAPDH_RT1R (5-GAAGACGCCAGTAGACTCCACGA-
CAT-3) and RnHPRTI_RT1R (5-CACAAGGGAAGTGA-
CAATCTACCTGACG-3). Quantitative real-time polymer-
ase chain reaction (qPCR) was performed with an iCycler
iQ apparatus (Bio-Rad, Amadora, Portugal), using primer
sets RnGRP1F (5-TCCTTCCTACCTCTACAACCGCCAA-
AA-3)/RnGRP1R to amplify rat GRP, RnGAPDH_RT1F (5-
CGGCAAGTTCAACGGCACAGTCAAG-3)/RnGAPDH_RT1R
to amplify rat glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH), and RnHPRTI_RT1F (5-AAATGTCTGTT-
GCTGCGTCCCTTTTGAT-3)/RnHPRTI_RT1R to amplify
rat HPRTI. PCR reactions, set up in duplicates, were
performed as previously described18 using Absolute
QPCR SYBR green fluorescein mix (ABgene, Epsom,
UK). Fluorescence was measured at the end of each
extension cycle in the FAM-490 channel and melting
profiles of each reaction were performed to check for
unspecific product amplification. Levels of gene expres-
sion were calculated using the comparative method
(Ct) and normalized using gene expression levels of
GAPDH or HPRTI housekeeping genes. Gene expression
in lung was set to 1 and used as reference for relative
expression in other tissues. qPCR was performed in qua-
druplicates and a normalized SD was calculated.
Histological Sample Preparation
Samples were collected as previously described18 and
included either in paraffin or in Historesin Plus (Leica
Microsystems, Lisbon, Portugal), according to the man-
ufacturer’s instructions. Mineral deposits were detected
with silver nitrate (Sigma-Aldrich, Taufkirchen, Germany)
by the von Kossa method, and physiological structures
were identified by counterstaining with hematoxylin and
eosin or toluidine blue.20
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In Situ Hybridization
A 417-bp fragment of rat GRP cDNA (spanning from
nucleotide 417 to the 3 end) cloned in pCRII-TOPO was
either linearized with ApaI and transcribed with SP6 RNA
polymerase to generate an antisense riboprobe or linear-
ized with KpnI and transcribed with T7 RNA polymerase
to generate a sense riboprobe. A 364-bp fragment of the
human GRP cDNA (spanning from nucleotide 459 to 822
according to EST sequences retrieved from GenBank
sequence data base and previously identified as GRP),18
amplified by PCR with HsGRPis2F (5-CATCCTATCTC-
TACAACCGCCACC-3) and HsGRPis1R (5-TTCAG-
CGTTTTTATTTGTAAGCCATA-3) primers and genomic
DNA, and cloned in pCRII-TOPO, was either linearized
with KpnI and transcribed with T7 RNA polymerase to
generate an antisense riboprobe or linearized with ApaI
and transcribed with SP6 RNA polymerase to generate a
sense riboprobe. Probes were then labeled with digoxi-
genin using RNA labeling kit (Roche, Mannheim, Ger-
many) according to the manufacturer’s instructions. RNA
in situ hybridization was performed on paraffin sections of
rat and human tissues with digoxigenin-labeled antisense
riboprobes, as previously described.18 Briefly, sections
were digested with 40 g/ml proteinase K (Sigma) in 1X
phosphate-buffered saline containing 0.1% Tween 20
(Sigma) for 30 minutes and then hybridized at 68°C over-
night in a humidified chamber. After hybridization, sec-
tions were washed and the signal revealed with the alka-
line phosphatase-coupled antidigoxigenin-AP antibody
(Roche) and nitro blue tetrazolium/5-bromo-4-chloro-3-
indolyl phosphate substrate solution (Sigma). Negative
controls for GRP mRNA detection were performed with
sense probes.
Production of Polyclonal Rabbit Antibody
(CTerm-GRP) against GRP
Affinity-purified rabbit polyclonal antibody against GRP
was obtained from SDI- Strategic Diagnostics (Newark,
DE), using for immunization a synthetic amino acid pep-
tide corresponding to the C terminus of rat GRP
(RQWHYDGLYPSYLYNRQNI), synthesized by NeoMPS,
Inc. (San Diego, CA), purified to 95% purity, and conju-
gated to keyhole limpet hemocyanin. A cysteine residue
was introduced at the N terminus of the peptide for bind-
ing to keyhole limpet hemocyanin. The affinity purified
antiserum was termed CTerm-GRP.
Protein Extraction and Detection from
Noncalcified Mammalian Tissues
Pig and rat skin (dermis and epidermis) and human blood
vessels were cleaned from fat tissue, lyophilized, and
reduced to fine powder. From the calculated weight a
10-fold excess (w/v) of 4 mol/L guanidine HCl (Sigma-
Aldrich) extraction solution was added with vigorous stir-
ring at 4°C for 24 hours, and the extracted material was
separated by centrifugation for 10 minutes at 10000  g.
A portion of these crude guanidine extract was dialyzed
against 50 mmol/HCI, using 3500 molecular weight tub-
ing (Spectra-Por 3, Spectrum, Gardena, CA) with four
changes of medium over 2 days and analyzed for the
presence of GRP by Western blotting using the purified
CTerm-GRP antibody. Rat GRP was further isolated from
the crude guanidine HCl extract by reverse-phase high
performance liquid chromatography as previously de-
scribed.18 Resulting fractions were analyzed for the pres-
ence of GRP and Gla-containing proteins by dot blot
using the CTerm-GRP and M3B (American Diagnostica,
Stamford, CT) antibodies, respectively.
For further isolation, pig guanidine HCl extract was
incubated with 0.1% hydroxyapatite (Calbiochem, San
Diego, CA) for 24 hours at 4°C, with constant rotation.
After incubation, hydroxyapatite was separated from the
crude extract by centrifugation for 10 minutes at 10000 
g. Hydroxyapatite was further cleaned by washing twice
with 6 mol/L guanidine HCl for 1 hour and twice with
distillated water for 30 minutes at room temperature with
constant stirring. The resulting hydroxyapatite powder
was demineralized using a 10-fold excess of 10% formic
acid for 4 hours at 4°C with vigorous stirring, as de-
scribed for bone demineralization18,21 and further dialyzed
against 50 mmol/L HCl as described above. Aliquots of the
formic acid dialyzed extract were analyzed by Western
blotting using the purified CTerm-GRP antibody.
Electrophoresis and Western Blotting
Aliquots of total protein were fractionated into a 4 to 12%
gradient polyacrylamide precast gel containing 0.1% so-
dium dodecyl sulfate (NuPage, Invitrogen), and protein
profile revealed by staining the gel as described.18,21
Transfer onto nitrocellulose membranes (Amersham Bio-
sciences, Carnaxide, Portugal) and protein immunode-
tection was performed as described previously.21,22 GRP
protein was detected by incubating blots overnight with 5
g/ml anti-CTerm-GRP antibody in 5% (w/v) nonfat dried
milk powder in Tris-buffered saline/Tween 20 (15 mmol/L
NaCl, 10 mmol/L Tris-HCl buffer, pH 8, 0.05% Tween 20)
as primary antibody and alkaline phosphatase-labeled
goat anti-rabbit IgG antibody (Sigma-Aldrich) diluted
1:30,000 in Tris-buffered saline/Tween 20, as secondary
antibody. Visualization of immunoreactive bands was
achieved using nitro blue tetrazolium/5-bromo-4-chloro-3-
indolyl phosphate substrate solution (Calbiochem) as
described.21,22
Dot Blotting
Samples of total protein were applied onto a nitrocellu-
lose membrane (Invitrogen) as previously described.22
GRP detection was performed using the purified CTerm-
GRP antibody as primary antibody and alkaline phos-
phatase-labeled goat anti-rabbit IgG (Sigma-Aldrich), as
secondary antibody. Gla-containing proteins were de-
tected using 5 g/ml of the purified monoclonal M3B
antibody (American Diagnostica) as primary antibody
and alkaline phosphatase-labeled goat anti-mouse IgG
as secondary antibody.
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Immunolocalization
Immunohistochemical staining experiments were per-
formed on paraffin and Historesin Plus-embedded tissue
sections as described.20,21 Briefly, the endogenous per-
oxidase activity was blocked with 3% H2O2 in Coons
buffer (CBT: 0.1 mol/L Veronal, 0.15 mol/L NaCl, 0.1%
Triton X-100) for 15 minutes. Nonspecific antibody bind-
ing was blocked with 0.5% (w/v) bovine serum albumin
directly after peroxidase activity blocking, or after treat-
ment with chondroitinase ABC (Sigma-Aldrich) (0.1 U/ml)
for 1 hour at 37°C. Incubation with the purified polyclonal
CTerm-GRP or the M3B antibodies (5 g/ml and 5 g/ml,
respectively, diluted in CBT), as primary antibodies, was
performed overnight in a humidified chamber at room
temperature. Peroxidase activity was detected using as
secondary antibodies the peroxidase-conjugated goat
anti-rabbit and anti-mouse IgG, respectively (Sigma-
Aldrich), and 0.025% 3,3-diaminobenzidine (Sigma-
Aldrich) as described.20,21 Negative controls consisted in
the substitution of the primary antibody with both normal
rabbit serum and CBT. Counterstaining was performed
with hematoxylin and eosin or toluidine blue.
Depletion of High Abundant Serum Proteins and
GRP Detection
Human and rat sera were prepared as described,23,24
quick-frozen in 1-ml aliquots on dry ice, and stored at
80°C until use. Depletion of the high abundant proteins
was performed for each 1 ml of human and rat serum
aliquots using the ProteoMiner kit (Bio-Rad), according to
the manufacturer’s instructions. Five microliters of each of
the eluted fractions was applied onto a nitrocellulose
membrane (Invitrogen). GRP detection was performed
with the purified CTerm-GRP antibody as described in
dot blotting.
Results
The GRP Gene Is Expressed Both in Skeletal
and in Soft Tissues
We have recently shown that GRP in sturgeon is ex-
pressed exclusively by cartilage-associated cells, while
in rat it was also expressed by bone cells. However, our
in silico analysis further suggested that GRP could be
present in other nonskeletal tissues.18 To continue these
studies and establish the pattern of GRP tissue distribu-
tion, we have determined its spatial levels of expression
in adult rat skeletal and soft tissues. Expression of GRP
was detected by real-time PCR in all 16 tissues analyzed,
the most significant levels being observed in cartilage-
and bone-containing tissues such as skull, inner ear, tail,
outer ear, and nose (see Supplemental Figure S1 at
http://ajp.amjpathol.org). However, the presence of higher
levels of expression in outer ear and nose, a result con-
firmed when using GAPDH to normalize GRP gene ex-
pression (results not shown), could not be easily ex-
plained. To further elucidate this question and clearly
establish the identity of GRP-expressing cells, we per-
formed in situ hybridization in sections from all rat tissues
expressing GRP. Interestingly, in sections of outer ear
(Figure 1) and nose (results not shown) GRP was found to
be highly expressed in skin and its appendages, at the
levels of epidermis and dermis. In rat outer ear skin, GRP
mRNA was detected in epidermis (Ep) (Figure 1, A and
D) and in all main structures housed in the dermis (De); in
the fibroblasts (Fb) that compose the reticular layer of the
dermis (Figure 1, B and D); in the hair follicles (HF)
(Figure 1, B and C); and in sweat (SwG) (Figure 1A) and
sebaceous (SG) (Figure 1, B and C) glands. Negative
controls were performed through hybridization of consec-
utive sections with GRP sense probe (Figure 1E), con-
firming the specificity of the signal observed in the above
described structures. Figure 1F shows GRP positive ex-
pression in an artery from the dermis of rat outer ear, with
higher expression found in vascular smooth muscle cells
(VSMC) of the tunica intima (TI), and lower expression in
the tunica media. In rat outer ear, GRP mRNA is also
expressed by elastic cartilage (EC) chondrocyte cells
(Cd) from all stages of differentiation (Figure 1G).
Figure 1. Rat GRP gene is highly expressed in nonskeletal tissues. Sites of
gene expression were determined by in situ hybridization with digoxigenin-
labeled antisense probes in outer ear paraffin sections, and signal was
revealed with alkaline phosphatase-coupled antidigoxigenin-AP antibody
and nitro blue tetrazolium /5-bromo-4-chloro-3-indolyl phosphate substrate
solution, yielding a characteristic blue color. GRP is highly expressed in the
skin and its appendages in both epidermis (Ep, A and D) and dermis (De, A
and D). Within the dermis GRP is detected in the fibroblasts (Fb, B and D),
hair follicles (HF, C), and sebaceous (SG, B and C) and sweat glands (SwG,
A). In blood vessels, GRP is detected mainly in vascular smooth muscle cells
(VSMC) of the tunica intima (TI, F). In the elastic cartilage (EC) composing
the outer ear, GRP is detected in chondrocyte (Cd) cells (G). Negative control
performed through in situ hybridization with GRP sense probe is presented
in E. Magnifications: A, D, E, 10; B, C, F, G, 20.
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These high levels of GRP expression found in both skin
and its appendages, as well as in the elastic cartilage,
which together constitute the main structures present in
rat nose and in outer ear, can explain the highest GRP
levels obtained in these tissues by qPCR (see Supple-
mental Figure S1 at http://ajp.amjpathol.org). The results
presented here, together with our previous findings,
clearly indicate that GRP is present in all types of carti-
lage. Also the presence of GRP mRNA in blood vessels
could explain the levels of GRP obtained by qPCR in all
irrigated organs.
In Soft Tissues, GRP Accumulates in Skin and in
the Vascular System
Specific GRP rabbit polyclonal antibodies (CTerm-GRP
antibody) were produced using a 19-amino-acid syn-
thetic peptide homologous to the C-terminal of rat GRP,
and cross-reactivity against GRP from other species was
checked by Western blot. The antibody was validated by
Western blot using purified sturgeon GRP18; a crude rat
skin extract, prepared using 4 mol/L guanidine HCl; a
crude pig skin extract, obtained as described above,
followed by a direct incubation with hydroxyapatite from
which proteins with affinity for this mineral phase were
eluted; and a crude guanidine extract of medium-size
human blood vessels with no apparent calcifications and
collected at autopsy. In all cases, a single positive immu-
noreactive band, with a migration profile similar to that of
sturgeon GRP, was obtained (see Supplemental Figure
S2A at http://ajp.amjpathol.org),18 indicating that GRP is
not only expressed but also accumulated in skin and/or in
vascular system in sufficient amounts to be detected from
a crude extract. Furthermore, our data provided evidence
that mammalian GRP shows a clear binding affinity for
hydroxyapatite.
To further confirm the -carboxylation status of the
protein, we further purified rat GRP from the skin guani-
dine crude extract using reverse-phase high perfor-
mance liquid chromatography as previously described.18
Individual peak fractions were analyzed for the presence
of GRP by dot blot using the CTerm-GRP antibody (re-
sults not shown) and the GRP peak containing fraction
was then further analyzed for the presence of Gla resi-
dues using the anti-Gla M3B antibody. Positive M3B an-
tibody immunoreaction was obtained by dot blot for rat
skin GRP (see Supplemental Figure S2B (rGRP) at http://
ajp.amjpathol.org),18 using as positive control, the purified
sturgeon GRP protein (see Supplemental Figure S2B
(StGRP) at http://ajp.amjpathol.org)18 whose -carboxyla-
tion status was previously confirmed by amino acid anal-
ysis.18 These results provided additional evidence for the
presence of -carboxylated residues in rat GRP isolated
from skin.
Spatial Profile of GRP Accumulation in Rat
Tissues
Sites of GRP accumulation were determined by immuno-
histochemistry in paraffin sections of several adult rat
tissues, using the CTerm-GRP antibody. In skeletal tis-
sues, GRP antigen was mainly detected inside cartilagi-
nous (Figure 2, A and B) and bony cells (Figure 2C),
following a pattern similar to that previously observed for
GRP mRNA.18,25 In the rat rib, GRP was localized in
mature (MC), columnar (CC), hypertrophic (HC) (Figure
2A), and immature (IC) (Figure 2B) chondrocytes, as well
as in compact bone osteocytes (Oc) (Figure 2C). In ad-
dition, when we performed a chondroitinase pretreatment
of the sections, we were able to detect GRP in the extra-
cellular matrix of calcified hypertrophic cartilage and in
the matrix surrounding the rib cartilage (results not
shown), in concordance with previously reported re-
sults.25 In skin, GRP accumulation also followed the pat-
tern of its mRNA distribution. It accumulated in epidermis
(Ep) (Figure 2, D and E), within those fibroblasts (Fb)
responsible for synthesis of dermis collagen elastic fibers
(Figure 2E), and in skin appendages, eg, hair follicles
(HF) (Figure 2D), sebaceous (SG) (Figure 2D), and sweat
(results not shown) glands. In the elastic cartilage (EC) of
Figure 2. Rat GRP is highly accumulated in cartilage (A, B, F), bone (C), skin
and its appendages (D and E), and in the vascular system (G–J) as deter-
mined by immunohistochemistry using the CTerm-GRP primary antibody
and peroxidase-conjugated goat anti-rabbit IgG as secondary antibody. Per-
oxidase activity was visualized using 3,3-diaminobenzidine substrate yielding
a brown color. A and B: Sites of GRP accumulation in sections of rib cartilage
showing protein detection inside chondrocytes in all stages of maturation:
columnar chondrocytes (CC), mature chondrocytes (MC), hypertrophic
chondrocytes (HC), and immature chondrocytes (IC). C: GRP detection in
bone sections showing protein inside osteocytes (Oc). D–F: GRP detection in
outer ear sections showing protein accumulation in skin epidermis (Ep) and
dermis (De, D and E) and its appendages: hair follicles (HF, D), sebaceous
glands (SG, D), and dermal fibroblast (Fb, E). In addition, GRP was detected
in chondrocytes (Cd) of the elastic cartilage (EC, F). G–J: GRP accumulation
in the vascular system in sections of outer ear (G and H), heart (I), and
kidney (J), showing GRP highly accumulated in the walls of blood vessels
(Bv) and capillaries (Cp). TM, tunica media; TI, tunica intima; EL, elastic
lamina. Magnifications: A–E and J, 10; F–H and I, 20.
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the outer ear, GRP was mainly detected inside the chon-
drocytes (Cd) (Figure 2F). The absence of signal in the
extracellular matrix was probably due to lack of chon-
droitinase pretreatment of these tissue sections. In addi-
tion to cartilage, bone and skin, the vascular system also
appears to be one of the primary sites of GRP accumu-
lation. Small and medium blood vessels from several
irrigated tissues showed high levels of GRP accumulated
in their walls, as can be observed in sections of rat outer
ear (Figure 2, G and H), heart (Figure 2I), and kidney
(Figure 2J).
GRP Accumulated in Skin and in Vascular
Tissues Is -Carboxylated
The pattern of distribution of Gla-containing proteins was
compared, in selected tissues, to that of GRP accumula-
tion through immunohistochemistry analysis. Studies
were performed on consecutive sections of rat outer ear
(Figure 3, A–C) and rib (Figure 3D) tissues using a mono-
clonal antibody that specifically recognizes Gla residues,
(M3B antibody). Until now, MGP was the only known Gla
protein that was associated with skin elastic fibers, al-
though mainly in pathological situations involving ectopic
calcifications.6 MGP was also the only known Gla con-
taining protein accumulated in cartilage, although with a
restricted pattern of distribution. We have previously
identified distinct patterns of GRP and MGP expression in
the cartilaginous cells of rat rib, clearly showing that MGP
is not expressed by hypertrophic chondrocytes of the
central zone of hyaline cartilage.18
The presence of Gla proteins within skin and cartilage
tissue sections was confirmed using the M3B antibody. In
rat skin, Gla proteins were detected in epidermis (Ep,
Figure 3, A and B), dermis (De), fibroblasts (Fb) of elastic
fibers (Figure 3, A–C), hair follicles (HF, Figure 3B), and
sebaceous (SG, Figure 3C) and sweat (results not
shown) glands. In cartilage, Gla proteins were detected
in all stages of chondrocyte differentiation, which in-
cluded the hypertrophic chondrocytes (CHC) of the cen-
tral zone (black star) where GRP is the only known Gla
protein expressed (Figure 3D). Although we cannot ex-
clude the possibility that, at these sites, other Gla con-
taining proteins in addition to GRP are being recognized
by the M3B antibody, the perfect co-localization ob-
served between M3B and CTerm-GRP antibody immuno-
localizations, together with our positive dot blot result
showing the presence of Gla residues in GRP from rat
skin obtained following reverse-phase high performance
liquid chromatography (see Supplemental Figure S2B at
http://ajp.amjpathol.org),18 strongly suggests that GRP is
in fact -carboxylated in these tissues.
GRP Is Also Expressed in Normal Human Skin
and in Vascular Tissues
The presence of high levels of GRP in rat skin and vas-
cular system raised the question of whether GRP had a
similar pattern of accumulation and expression in human
tissues. Human GRP mRNA localization and protein ac-
cumulation were detected in paraffin embedded sections
of healthy human skin by in situ hybridization (Figure 4,
A–C) and immunohistochemistry using the previously val-
idated CTerm-GRP antibody (Figure 4, D–F). The pattern
of human GRP accumulation in skin (Figure 4, D–F) fol-
lows the pattern of mRNA localization (Figure 4, A–C),
which is similar to the results we obtained for rat GRP
(Figure 1, A–C). In human skin, GRP is detected at the
epidermis and dermis (Figure 4, A and D) levels, being
highly expressed and accumulated in fibroblasts (Fb) of
both papillary and reticular dermis (Figure 4, A and D), in
hair follicles (HF, Figure 4, B and E), in sweat (SwG)
(Figure 4, C and F) and sebaceous (results not shown)
glands, and in small blood vessels and capillaries (Cp)
that irrigate the skin (Figure 4A).
After showing by Western blot that GRP was present in
human vascular system (see Supplemental Figure S2A at
http://ajp.amjpathol.org),18 the detailed pattern of GRP
accumulation was evaluated in carotid samples obtained
at autopsy. Samples were embedded in paraffin and
analyzed by immunohistochemistry using the CTerm-
GRP antibody (Figure 4, G–I). Histomorphological evalu-
ations were performed by staining consecutive sections
with hematoxylin and eosin, and the presence of mineral
deposits was monitored by von Kossa staining. At sites
showing normal histomorphological features and ab-
sence of calcification (results not shown), GRP was found
mainly associated with vascular smooth muscle cells
(VSMC) of the tunica media (TM, Figure 4, G and H), and
in small blood vessels (Bv) irrigating the tunica adventitia
(TA, Figure 4, G and I). The apparent lack of GRP in the
extracellular matrix could be due to the absence of pro-
tein accumulation in normal, non-pathological conditions,
as also described for MGP in normal blood vessels.5
Figure 3. Gla proteins detection co-localize in rat skin and cartilage with
GRP accumulation. Immunolocalization of Gla proteins was performed using
the Gla-specific monoclonal antibody M3B, and peroxidase-conjugated goat
anti-mouse IgG as secondary antibody, in sections of rat outer ear (A–C) and
rib (D), showing a positive co-localization (brown) with GRP, presented in
Figure 2. De, dermis; Ep, epidermis; Fb, fibroblasts (arrowheads); SG,
sebaceous gland; and HF, hair follicle. CHC, cartilage of the hypertrophic
zone. Black star is located within the calcified cartilage. Magnification, 10.
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GRP Is Highly Accumulated at Sites of Ectopic
Calcification in Human Skin and in the Vascular
System
The in vivo calcium mineral binding properties of GRP
were originally detected by our results in sturgeon, since
the protein was found to accumulate in the mineralized
branchial arches, being extracted using a selective acid
demineralization procedure.18 We now show, using an in
vitro assay, that pig GRP has the ability to bind to hy-
droxyapatite crystals, suggesting the possibility of GRP
being associated with ectopic mineralization of connec-
tive tissue, either in skin or in vascular system or both. To
address this question, the CTerm-GRP antibody was
used for GRP immunolocalization in human samples de-
rived from patients diagnosed with skin and vascular
system-associated calcification pathologies (Figures 5
and 6, respectively). The presence of mineral deposits in
samples from patients diagnosed with dermatomyositis
with calcinosis (Figure 5, A–C) and PXE (Figure 5, D–F)
were identified by von Kossa staining (Figure 5, C and F),
and presence of GRP accumulated at the same sites was
detected by immunohistochemistry (Figure 5, A, B, D,
and E). Consecutive sections incubated in the same con-
ditions but without the CTerm-GRP antibody (NC insets in
Figure 5, A and D) were used as negative controls. GRP
was found to be highly accumulated at sites of calcifica-
tion in both pathological situations, either when massive
calcified material was deposited in the reticular dermis
(Figure 5, A and B) or when small calcified spots were
diffused along the elastic fibers (Figure 5, D and E).
Results clearly show that GRP is associated with the
mineralized material since mineral staining and GRP ac-
cumulation are clearly co-localized.
Figure 4. GRP is present in human skin (A–F)
and vascular system (G–I). A–C: Sites of GRP
expression determined by in situ hybridization
with digoxigenin-labeled antisense probes
(blue) in healthy human skin. D–F: Sites of GRP
accumulation determined by immunohisto-
chemistry with the CTerm-GRP primary anti-
body and peroxidase-conjugated goat anti-rab-
bit IgG as secondary antibody (brown), in
healthy human skin. D–F show consecutive sec-
tions of A–C. Human GRP is detected in skin at
the levels of epidermis (Ep) and dermis (De, A
and D), small capillaries (Cp, A), and skin ap-
pendages (B, C, E, F), similarly to what is ob-
served for rat GRP (Figures 1 and 2). Fb, fibro-
blast; HF, hair follicle; SwG, sweat gland. G–I:
GRP accumulation in noncalcified human ca-
rotids showing GRP in vascular smooth muscle
cells (VSMC) located in the tunica media (TM, G
and H), and in small blood vessels (Bv) of the
tunica adventitia (TA, G and I). Magnifications:
A–G, 10; H and I, 20.
Figure 5. GRP is highly accumulated at sites of
pathological calcification in human skin diag-
nosed with dermatomyositis with calcinosis
(DC) (A–C) and PXE (D–F). Sites of GRP accu-
mulation were determined by immunohisto-
chemistry using the CTerm-GRP primary anti-
body and peroxidase-conjugated goat anti-
rabbit IgG as secondary antibody (brown
pointed by arrows, A and B, D and E). Mineral
detection was achieved by staining consecutive
sections of DC and serial sections of PXE with
silver nitrate by the von Kossa staining method
(open arrows, C and F, respectively). In both
pathological situations, GRP is co-localized with
sites of mineral deposition, either in DC samples
when massive mineral deposits are present (A
and B) or in PXE samples where disperse small
mineral spots are detected (D and E). A–C were
counterstained with toluidine blue and F with
hematoxylin and eosin. Negative controls were
performed by omitting the CTerm-GRP antibody
in consecutive sections of DC (NC, inset in A)
and PXE (NC, inset in D) samples. Magnifica-
tion, 10.
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Arterial calcification is a very common process that
normally progresses with age, and in fact, up to 95% of
men and women at autopsy show coronary artery calci-
fication regardless of death cause.3 Also, among the
normal population, patients with chronic kidney disease
(CDK) are a high risk group for development of vascular
calcifications.26 The pattern of GRP accumulation was
thus studied in a group of patients with CDK (Figure 6, B
and D) and in a group of samples collected at autopsy
from vascular tissue showing ectopic calcifications (Fig-
ure 6, F and H), as detected by von Kossa staining
(Figure 6, A, C, E, and G). In both groups, the calcifica-
tion observed by von Kossa staining was at the media
level, characterized by the absence of macrophages and
lipids.
Our results provided clear evidence that GRP was
highly accumulated at sites of medial calcification, either
in mildly calcified arteries, showing disperse mineral de-
posits (Figure 6, B and F), or in extensive and advanced
lesions (Figure 6H). In cases where calcification was
homogenously dispersed along the fibers of the tunica
media (Figure 6A), GRP was detected both inside the
vascular smooth muscle cells and in the extracellular
matrix (Figure 6B), in contrast with its almost absence in
noncalcified areas (Figure 6, C and D). When calcifica-
tion was localized, either as disperse (Figure 6E) or mas-
sive (Figure 6G) mineral deposits, GRP was easily iden-
tified as co-localizing with the mineral (Figure 6, F and H).
This high accumulation of the protein at sites of mineral
deposits, in contrast with its absence in the extracellular
matrix detected in normal situations, reveals that GRP is
definitively associated with the processes of abnormal
calcification in the vascular system.
Discussion
Our recent discovery of GRP, a new VKD protein origi-
nally purified from sturgeon mineralized cartilage and
presenting highly conserved orthologs in all vertebrate
groups, an unprecedented high density of Gla residues,
and a strong association with cartilaginous tissues, lead
us to suggest a function for GRP in the regulation of
calcium in the extracellular matrix environment.18 Al-
though in sturgeon GRP was mainly associated with car-
tilaginous tissues, in rat we have previously shown that
GRP was also expressed in bone cells.18 In the present
report we show that GRP in rat and human is also ex-
pressed and accumulated in the skin and in the vascular
system. Our results of immunohistochemistry and West-
ern blot were performed using a newly developed anti-
body that was validated, in addition to sturgeon GRP, for
all mammalian species used, which included rat, pig, and
human. Moreover, we were able to confirm that rat GRP is
-carboxylated using a Gla-specific antibody, reinforcing
the previously proposed theory that GRP should be
-carboxylated in all species.18
The high levels of GRP found in the skin, although
surprising, cannot be considered as unexpected. Since
the late 1970s, a relation between Gla proteins and skin
has been suggested. The presence of -carboxylase
activity in both epidermal and dermal tissue and the
accumulation of non-carboxylated precursor proteins in
both dermal and epidermal microsomes after warfarin
treatment,17 together with the reported occurrence of
Gla-containing proteins in pathological depositions of
calcified material in skin of patients suffering from sclero-
derma and dermatomyositis,27,28 pointed to the presence
of a still unknown Gla protein localized in skin, with a role
in skin calcium metabolism and involved in the regulation
of the calcification process.17 In fact, the strongest re-
ported evidences for the presence of Gla-containing pro-
teins in skin emerged from studies involving skin patho-
logical situations with ectopic mineralization.
Human skin is an organ containing the complete bio-
chemical machinery to develop calcification, as shown
by the high abundance of reported pathologies ranging
from mild to severe skin calcifications (dermatomyositis,
scleroderma, PXE, Keutel syndrome, among others), al-
though the molecular mechanisms behind this ectopic
calcifications have only started to be elucidated. The
reported effect of warfarin in these skin pathologies is still
controversial. While sometimes a profound and rapid
decrease of the calcified lesions with complete disap-
pearance has been reported,29,30 more often other au-
thors have described a pathological effect of warfarin in
the skin30,31 and related it to the inhibition of -carboxy-
Figure 6. GRP is highly accumulated in the human vascular system at sites of
pathological calcification of human arteries from both CDK patients (A–D)
and postmortem samples (pM) (E–H). Sites of GRP accumulation were
determined by immunohistochemistry using the CTerm-GRP primary anti-
body and peroxidase-conjugated goat anti-rabbit as secondary antibody
(brown) (B, D, F, H), and mineral detection was achieved by staining
consecutive sections of both CDK and pM with silver nitrate by the von Kossa
staining method (A and C and E and G, respectively). In CDK samples GRP
is highly accumulated at sites showing mineral deposition (A and B), when
compared with non-calcified areas (C and D). In pM samples GRP is co-
localized with sites of disperse (E and F) and massive (G and H) calcification.
E–H were counterstained with toluidine blue. Magnification, A–G, 10.
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lation of local Gla-containing proteins. Until now, the iden-
tity of this skin Gla protein has not been clearly eluci-
dated, but the recent and strong association of MGP with
several skin pathologies,6–9,32 and in particularly to the
presence of different processed forms of this pro-
tein,7,14,32 supports and points to an essential role of
MGP in the prevention of these skin calcifications.
PXE, an autosomal recessive disease characterized by
a progressive mineralization of connective tissue result-
ing in skin, arterial, and eye disease, can be divided into
the classical PXE, caused by mutations in the ABCC6
gene, which encodes an ABC transporter protein,13 and
the so called PXE-like, identified more recently, as being
caused by missense mutations in the -glutamyl carbox-
ylase (GGCX) gene.15,33 Either by direct reduction of
carboxylation, caused by reduced GGCX activity,14,15 or
by a deficiency in the reduced form of vitamin K, an
obligatory cofactor for carboxylation, postulated to be
transported from the liver into circulation and peripheral
tissues by the ABCC6 transporter,34 it is now assumed
that ectopic mineralization, the pathological hallmark of
PXE clinical manifestations, is caused by a local tissue
deficiency in vitamin K-dependent protein carboxylation.
Again, functional MGP has being assumed as having an
essential role in preventing aberrant mineralization.6,8,13,14
The discovery of GRP in skin and, moreover, its strong
association with abnormal calcifications in both PXE and
dermatomyositis patients, shown by the high accumula-
tion of protein co-localized with the mineral deposits,
strongly suggest that GRP may be the unknown skin Gla
protein that remained elusive until now, and a new impor-
tant player in modulating skin ectopic mineralization. Al-
though MGP is widely accepted as one of the strongest
physiological inhibitors of soft tissue calcification known
to date, and its association with skin mineralization has
been proved, it was never clearly established whether
MGP is produced/accumulated in normal skin, as it is in
cartilage, bone matrix, and arterial walls.5 On the con-
trary, GRP is systemically synthesized and accumulated
in skin, as shown by the high levels of mRNA and protein
found both in rat and human, which suggests that GRP is
a naturally occurring agent affecting ectopic skin calcifi-
cation. Moreover, MGP-deficient knockout mice manifest
extensive calcification of the aorta and articular cartilage,
dying by artery rupture within the first 2 months of age.35
However, there is no reported phenotype relating it to
skin calcifications. Furthermore, Keutel syndrome, which
is characterized by loss-of-function mutations in the MGP
gene, result in abnormal calcification of the soft tissues
with diffuse cartilage calcification and short terminal pha-
langes. Other findings include peripheral pulmonary ste-
nosis, hearing loss, dysmorphic facies and mental retar-
dation,36 but abnormal skin changes are not reported in
patients with Keutel syndrome. However, a new variant of
Keutel syndrome characterized by a new MGP mutation
recently identified in a consanguineous family, showed
overlapping features of cutis laxa.37 Whether loss of MGP
function can explain all of the clinical manifestations ob-
served within these patients, in particular the skin alter-
ations, was further discussed and questioned, and other
possibilities such as additional unidentified mutations in
other genes were suggested.16
Besides skin, we found GRP highly accumulated in
small and medium size blood vessels in rat, and we were
able to confirm its presence in the human vascular sys-
tem, both by immunohistochemistry and Western blot.
Furthermore, we show high accumulation of the protein
co-localized with mineral deposits in situations of mas-
sive and disperse mineralization, associated with media
calcification. Although the presence of Gla proteins in the
vascular system is known, as is the case of MGP and
Gas6, our discovery of a new Gla protein also present in
the same tissues raises many questions about previously
reported work describing phenotypes based solely on
general interference in -carboxylation mechanisms.
Our work underlines the need for a strict re-evaluation
of the role of each target Gla protein involved in vascular
calcification and the elucidation of their corresponding
specific functions. It has been shown that inhibiting ex-
trahepatic -carboxylation by warfarin induces vascular
media calcification in rats,10,38 consistent with the finding
that in human, high vitamin K intake is associated with low
aorta calcification39 and beneficial effects on the elastic
properties of the vessel wall.40 Moreover a high vitamin K
intake can reverse pre-existing arterial calcification in
rats.11 As vitamin K is an essential cofactor in the -car-
boxylation reaction catalyzed by the -glutamyl carbox-
ylase, and warfarin prevents -carboxylation, interfering
with the VKOR enzyme, responsible for the vitamin K
recycling, it is conceivable that some of the effects ob-
served with warfarin and/or vitamin K administration are
due to impairment and/or improvement of GRP function.
Although emerging in vitro and whole animal data sug-
gest that warfarin may induce vascular calcification,4,41
always through a proposed relation with the under-car-
boxylation of MGP, this has not yet been well studied in
humans.
In rats, MGP has been extensively shown to be a
vascular calcification inhibitor, with widespread and ex-
tensive vascular calcification in the MGP knockout mice35
and phenotype rescue after restoration of MGP expres-
sion.42 However, in humans, MGP loss of function, as in
Keutel syndrome, show less severe vascular calcifica-
tions, suggesting additional agents or more complex
mechanisms preventing arterial calcification. The exis-
tence of other inhibitors, yet to be found, that function to
prevent ECM calcification, in particular in tissues as skin,
has been previously suggested.1 The structural property
of GRP, with an uncommonly extensive Gla domain show-
ing high mineral-binding affinity, its presence in normal
soft tissues like skin and vascular system, and its asso-
ciation with ectopic mineral deposits, is consistent with a
putative role for GRP as being a naturally occurring mod-
ulator of calcium availability in the ECM and thus a po-
tential inhibitor of cardiovascular and skin calcifications,
constitutively expressed, acting by directly influencing
mineral formation.
The complex chemical nature of GRP, as all other VKD
proteins, which are strictly dependent on their Gla resi-
dues for proper function,5,12 indicates the need of addi-
tional studies concerning the evaluation of GRP -car-
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boxylation status accumulated at the mineral deposits,
both in skin and blood vessels. Antibodies specific to
both forms, -carboxylated (Gla-GRP) and non-carboxy-
lated (Glu-GRP), are currently under development (Geno-
Gla Diagnostics, Faro, Portugal) and will be a valuable
tool for further studies on GRP function. Similar to what
was suggested for MGP,12,14 Gla and Glu-GRP forms
may have different patterns of accumulation, with differ-
ent roles in the mineralization process, and this can be
dependent on the vitamin K bioavailability in these pe-
ripheral tissues.
To access whether GRP was present in blood serum,
we used the ProteoMiner kit (Bio-Rad, Amadora, Portu-
gal) to remove the most abundant serum proteins from rat
and human serum. Using this approach together with the
validated CTerm-GRP antibody, we were able to detect
GRP, as one of the less abundant circulating proteins
present in rat and human serum (results not shown). The
evidence for the presence of GRP in blood opens new
perspectives for future studies aiming to establish a re-
lationship between levels of circulating Gla and Glu-GRP
and the degree of vascular and skin calcifications. We
are currently developing a GRP enzyme-linked immu-
nosorbent assay (GenoGla Diagnostics, Faro, Portugal)
that will be able to differentiate the possible forms of GRP
circulating in serum. This assay could be used to monitor
serum GRP levels in relation with a given pathology and
establish its potential use as tool suitable for diagnostic
and prognostic evaluation of skin and vascular calcifica-
tion risk association. Further understanding of the mech-
anisms and active players involved in the occurrence of
pathological extracellular matrix calcification should offer
a potential hope for the development of new therapeutic
strategies to control these processes.
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